
    
      A Phase 2a, two-center, randomized, double-blind, placebo-controlled study in which subjects
      will be randomized to receive either BOL-DP-o-04 or placebo in addition to Standart of Care.
      The study evaluates the effect of BOL-DP-o-04 for Diabetic Neuropathy. The study includes a
      screening period up to three weeks followed by a 12-week treatment period
    
  